Manasi Patwardhan Joins BioSig as Director of Strategic Planning
July 11 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
device company developing a proprietary biomedical signal
processing technology platform designed to address an unmet need
for the electrophysiology (EP) marketplace, today announced that
Ms. Manasi Patwardhan joined the Company as Director of Strategic
Planning.
Ms. Patwardhan brings to BioSig over 18 years of program
management and product development experience with several Fortune
500 companies in the medical technology, pharma and healthcare
verticals. A biomedical engineer by training, Ms. Patwardhan’s core
competencies span manufacturing and vendor management, systems
engineering, cross-functional team leadership and process
improvements. Most recently, Ms. Patwardhan was in a technical
program management role at Verily Life Sciences, LLC, an Alphabet,
Inc. company, a role, in which she led hardware development for a
class III therapy technology program as well as supply-chain and
vendor management. Prior to that, Ms. Patwardhan was employed by
Boston Scientific - Neuromodulation, where she was responsible for
delivering a range of technology and product development programs,
including commercially launched products in the Spinal Cord
Stimulation portfolio as well as a connected health eco system.
Earlier in her career Ms. Patwardhan was with Medtronic Diabetes,
where she led product development efforts for class II therapy,
diagnostic and combination products. Her work involved the delivery
of engineering solutions from cross-functional teams comprising
human factors, marketing, industrial design, hardware and software
design and third-party vendors. Ms. Patwardhan holds a Master of
Science in Biomedical Engineering from the University of Southern
California Los Angeles and Bachelor of Engineering, Chemical
Engineering from University of Pune, India.
“Manasi impressed us with her accomplishments in strategic
delivery of complex engineering projects. Her expertise in
successfully navigating the fast-paced product development
environment will be of significant value to our growing
operations,” stated Kenneth L. Londoner, Founder, Chairman and CEO
of BioSig Technologies, Inc.
BioSig recently announced that it has been added to the Russell
3000 Index and was allowed 33 patent claims covering its PURE EP™
System. In the first half of 2019 BioSig successfully conducted
first patient cases using its PURE EP™ System at the Texas Cardiac
Arrhythmia Institute in Austin, TX, Greenville Memorial Hospital in
Greenville, SC and Indiana University School of Medicine. These
initial experiences suggested improved cardiac signal detection and
fidelity.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP™ System. The
technology has been developed to address an unmet need in a large
and growing market.The Company’s first product, PURE EP™ System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory. The system is indicated for use under the
supervision of licensed healthcare practitioners who are
responsible for interpreting the data. This novel cardiac signal
acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during
electrophysiology procedures in patients with abnormal heart rates
and rhythms. BioSig’s ultimate goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
310-620-9320
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024